MALVERN, Pa., March 21, 2022 (World NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a scientific-stage biopharmaceutical enterprise concentrated on getting, developing, and commercializing gene therapies to treatment blindness health conditions and building a vaccine to help you save life from COVID-19, today introduced the appointment of Jessica Crespo, CPA, as Main Accounting Officer and Senior Vice President, Finance. She assumed the role effective March 18, 2022.
In this role, she will be dependable for the progress and execution of the Company’s fiscal system, as very well as all corporate finance, accounting, and internal and external financial reporting capabilities. She will serve as a member of Ocugen’s management team, reporting right to the CEO.
Ms. Crespo has additional than 20 several years of encounter in accounting and economical leadership. She has been with Ocugen considering the fact that 2019, beforehand serving as Vice President, Company Controller and Treasurer. Ahead of becoming a member of the Corporation, she held fiscal management roles in Aerie Pharmaceuticals, Aralez Prescribed drugs and Cubist Prescription drugs the place she was accountable for financial and technological accounting and SEC reporting, such as the implementation of new accounting criteria and the accounting and reporting of elaborate transactions. Prior to that, Ms. Crespo was a senior manager in Ernst & Young’s audit and assurance follow.
“Jess has been an essential member of the Ocugen staff for just about 3 decades and we are delighted to figure out her valuable contributions with this expansion of her purpose. The Organization has seen transformational growth around the past year, as we do the job to advance the therapies in our pipeline toward regulatory acceptance. Jess’ knowledge and experience will enable us sustain that momentum,” said Dr. Shankar Musunuri, Chairman of the Board, Main Govt Officer, and Co-founder of Ocugen.
Ms. Crespo holds a Bachelor of Science in Accounting from Boston School and is a Accredited General public Accountant.
About Ocugen, Inc.
Ocugen, Inc. is a medical-phase biopharmaceutical business concentrated on finding, producing, and commercializing gene therapies to treatment blindness conditions and producing a vaccine to preserve lives from COVID-19. Our breakthrough modifier gene therapy system has the likely to handle numerous retinal ailments with a single drug — “one to lots of,” and our novel biologic solution candidate aims to supply far better remedy to sufferers with underserved health conditions these kinds of as soaked age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine prospect for COVID-19 in the U.S. and Canadian markets. For more details, you should go to www.ocugen.com.
Cautionary Take note on Ahead-Searching Statements
This push release has forward-searching statements in just the meaning of The Non-public Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may perhaps, in some cases, use terms these kinds of as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other phrases that express uncertainty of foreseeable future gatherings or outcomes to establish these forward-seeking statements. These types of statements are subject matter to numerous critical variables, challenges and uncertainties that may possibly lead to actual situations or final results to vary materially from our recent anticipations. These and other challenges and uncertainties are additional thoroughly described in our periodic filings with the Securities and Exchange Commission (“SEC”), such as the hazard aspects described in the part entitled “Risk Factors” in the quarterly and once-a-year reports that we file with the SEC. Any forward-hunting statements that we make in this press launch communicate only as of the date of this push release. Besides as expected by legislation, we think no obligation to update forward-on the lookout statements contained in this press launch no matter if as a final result of new details, long run functions or in any other case, soon after the date of this press launch.
Head, Investor Relations & Communications